Clinical commissioning policy: Combination brentuximab vedotin and bendamustine for patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma

Document first published:: 16 July 2026
Page updated:: 25 August 2026
Topic:: Specialised commissioning
Publication type:: Policy or strategy, Report

Brentuximab vedotin and bendamustine is recommended to be available as a routine commissioning treatment option for patients aged 8 years and above in relapsed and refractory classical Hodgkin lymphoma within the criteria set out in this document.

Document

$Clinical commissioning policy: Combination brentuximab vedotin and bendamustine (BVB) for patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma$

Clinical commissioning policy: Combination brentuximab vedotin and bendamustine (BVB) for patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma

PDF
286 KB
8 pages

Summary

Published 16 July 2026.

Document

$CPAG summary report: BVB for patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma$

CPAG summary report: BVB for patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma

PDF
292 KB
13 pages

Summary

PDF format. Published 25 August 2026.

Document

$Clinical panel report: BVB for patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma$

Clinical panel report: BVB for patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma

PDF
160 KB
3 pages

Summary

PDF format. Published 25 August 2026.

Document

$Evidence review (children): BVB for children with relapsed or refractory classical Hodgkin lymphoma$

Evidence review (children): BVB for children with relapsed or refractory classical Hodgkin lymphoma

PDF
661 KB
49 pages

Summary

PDF format. Published 25 August 2026.

Document

$Evidence review (adults): BVB for adults with relapsed or refractory classical Hodgkin lymphoma$

Evidence review (adults): BVB for adults with relapsed or refractory classical Hodgkin lymphoma

PDF
1 MB
91 pages

Summary

PDF format. Published 25 August 2026.

Document

$Engagement report: BVB for patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma$

Engagement report: BVB for patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma

PDF
219 KB
5 pages

Summary

PDF format. Published 25 August 2026.

Document

$EHIA: BVB for patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma$

EHIA: BVB for patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma

PDF
230 KB
17 pages

Summary

PDF format. Published 25 August 2026.